STOCK TITAN

Director Julie Smith (EXEL) receives 8,367 RSUs vesting in 2027

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Smith Julie reported acquisition or exercise transactions in this Form 4 filing.

EXELIXIS, INC. director Julie Smith reported an equity compensation grant of 8,367 restricted stock units on May 27, 2026. The award carries no purchase price and each unit is economically equivalent to one share of common stock.

The RSUs will vest in full on May 27, 2027, provided she remains in continuous service through that date. Following this grant, Smith is shown as holding 28,957 shares of common stock, including the shares that will be issued upon vesting of these RSUs.

Positive

  • None.

Negative

  • None.
Insider Smith Julie
Role null
Type Security Shares Price Value
Grant/Award Common Stock 8,367 $0.00 --
Holdings After Transaction: Common Stock — 28,957 shares (Direct, null)
Footnotes (1)
  1. Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 27, 2027, subject to the Reporting Person's continuous service through that date. Includes 8,367 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs.
RSUs granted 8,367 units Restricted stock units granted on May 27, 2026
Grant price $0.00 per share Equity award granted at no purchase price
Vesting date May 27, 2027 RSUs vest 100% on this date, subject to service
Total shares after grant 28,957 shares Common stock holdings following transaction, including RSU shares
restricted stock units ("RSUs") financial
"Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2017 Equity Incentive Plan financial
"granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan"
continuous service financial
"The RSUs will vest as to 100% of the shares ... subject to the Reporting Person's continuous service through that date"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Smith Julie

(Last)(First)(Middle)
C/O EXELIXIS, INC.
1851 HARBOR BAY PARKWAY

(Street)
ALAMEDA CALIFORNIA 94502

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
EXELIXIS, INC. [ EXEL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/27/2026A8,367(1)A$028,957(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 27, 2027, subject to the Reporting Person's continuous service through that date.
2. Includes 8,367 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs.
Remarks:
/s/ Nina Ayer, Attorney in Fact05/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did EXEL (Exelixis) director Julie Smith report on this Form 4?

Julie Smith reported receiving 8,367 restricted stock units as equity compensation. The award is in Exelixis common stock equivalents, granted at no cost, and reflects a non-market transaction rather than an open-market purchase or sale of EXEL shares.

How many Exelixis (EXEL) RSUs were granted to Julie Smith and on what date?

Julie Smith was granted 8,367 restricted stock units on May 27, 2026. Each RSU is economically equivalent to one share of Exelixis common stock, forming part of her director compensation under the company’s equity incentive plan.

When do Julie Smith’s Exelixis (EXEL) RSUs vest according to the filing?

The RSUs vest 100% on May 27, 2027, if Julie Smith remains in continuous service through that date. Upon vesting, 8,367 shares of Exelixis common stock will be issued to her, converting the RSUs into actual shares.

What is Julie Smith’s total Exelixis (EXEL) share position after this RSU grant?

After the grant, Julie Smith is shown holding 28,957 shares of Exelixis common stock. This figure includes 8,367 shares that will be issued in the future when her newly granted restricted stock units vest in May 2027.

Did Julie Smith buy or sell Exelixis (EXEL) shares on the open market?

The transaction is a grant of restricted stock units, not an open-market trade. The units were awarded at a price of $0.00 per share as part of compensation, so there was no market purchase or sale of EXEL shares involved.